Compare · NTRA vs TLSI
NTRA vs TLSI
Side-by-side comparison of Natera Inc. (NTRA) and TriSalus Life Sciences Inc. (TLSI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRA and TLSI operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $31.91B, about 155.6x TLSI ($205.1M).
- Over the past year, NTRA is up 33.2% and TLSI is down 37.5% - NTRA leads by 70.8 points.
- NTRA has been more active in the news (18 items in the past 4 weeks vs 8 for TLSI).
- NTRA has more recent analyst coverage (25 ratings vs 6 for TLSI).
- Company
- Natera Inc.
- TriSalus Life Sciences Inc.
- Price
- $220.03-1.27%
- $3.46+3.59%
- Market cap
- $31.91B
- $205.1M
- 1M return
- +10.42%
- -23.96%
- 1Y return
- +33.23%
- -37.55%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2021
- News (4w)
- 18
- 8
- Recent ratings
- 25
- 6
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest NTRA
- Director Marcus Gail Boxer sold $2,389,328 worth of shares (11,000 units at $217.21) and exercised 11,000 shares at a strike of $22.83 (SEC Form 4)
- SEC Form 3 filed by new insider Lynch Thomas J. Jr.
- CEO AND PRESIDENT Chapman Steven Leonard sold $9,089,776 worth of shares (41,124 units at $221.03) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 108,743 units (SEC Form 4)
- Natera Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $655,295 worth of shares (3,000 units at $218.43) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 137,643 units (SEC Form 4)
- Director Rubin Eric H was granted 2,124 shares, increasing direct ownership by 42,480% to 2,129 units (SEC Form 4)
- Director Botha Roelof sold $17,184,092 worth of shares (78,000 units at $220.31) (SEC Form 4)
- Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
- Wolfe Research resumed coverage on Natera with a new price target
Latest TLSI
- TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
- Amendment: SEC Form SCHEDULE 13G/A filed by TriSalus Life Sciences Inc.
- Chief Commercial Officer Marshak Richard sold $1,450 worth of shares (543 units at $2.67), decreasing direct ownership by 0.43% to 125,101 units (SEC Form 4) to cover withholding tax
- Director Wahlstrom Mats bought $151,800 worth of shares (60,000 units at $2.53), increasing direct ownership by 69% to 147,555 units (SEC Form 4)
- Director Stansky Michael P bought $1,525,000 worth of shares (610,000 units at $2.50), increasing direct ownership by 49% to 1,240,722 units (SEC Form 4)
- Chief Financial Officer Patience David bought $17,253 worth of shares (7,100 units at $2.43), increasing direct ownership by 3% to 275,757 units (SEC Form 4)
- CEO and President Szela Mary T bought $102,776 worth of shares (39,682 units at $2.59), increasing direct ownership by 4% to 1,065,215 units (SEC Form 4) to cover withholding tax
- Director Gordon Gary B. bought $24,600 worth of shares (10,000 units at $2.46), increasing direct ownership by 16% to 72,510 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by TriSalus Life Sciences Inc.
- Director Gordon Gary B. was granted 52,754 shares, increasing direct ownership by 541% to 62,510 units (SEC Form 4)